CGRP Receptor Antagonists for Non-Oral Migraine Delivery
Solution Overview
Problem
Current CGRP receptor antagonists for migraine treatment often require frequent administration and are associated with liver toxicity, limiting their clinical use due to elevated liver transaminases levels.
Innovation Solution
Development of novel compounds with high affinity and solubility for non-oral routes of administration, such as sub-cutaneous, intravenous, and intranasal delivery, which differ from oral molecules in molecular profile, to minimize liver burden and avoid first-pass exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral CGRP receptor antagonists are used for migraine treatment, then they can be administered orally for convenience, but they cause elevated liver transaminases levels and require frequent administration
Solution Approach 1:
The patent changes the administration route parameter from oral to non-oral routes (sub-cutaneous, intravenous, intranasal), which fundamentally alters how the drug is processed by the body, avoiding first-pass liver metabolism and reducing liver toxicity while maintaining therapeutic effectiveness
Solution Approach 2:
The patent introduces alternative delivery pathways (sub-cutaneous injection, intravenous injection, intranasal administration) as intermediaries between the drug and the target receptor, bypassing the harmful oral absorption-liver metabolism pathway
2Ease of operation
If oral CGRP receptor antagonists are used, then they can be easily administered, but they are associated with frequent administration requirements
Solution Approach 1:
The patent changes the pharmacokinetic parameters by switching from oral to non-oral administration routes, which results in different absorption rates, bioavailability profiles, and duration of action, thereby reducing the frequency of administration while maintaining ease of use
3Object-affected harmful factors
If novel compounds with high affinity are developed for non-oral routes, then liver injury risks are reduced, but the molecular profile and formulation requirements become more complex
Solution Approach 1:
The patent modifies the molecular properties and physicochemical parameters of CGRP receptor antagonists specifically for non-oral routes of administration, optimizing parameters such as solubility, stability, and molecular size to suit sub-cutaneous, intravenous, or intranasal delivery while avoiding liver metabolism issues
Data Source
AI summary
The disclosures herein relate to novel compounds of formulawherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.



